A Phase 1/2 Study of SNDX-275 in Combination With Imatinib for Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
Phase of Trial: Phase I/II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Entinostat (Primary) ; Imatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2013 Actual end date changed from Jan 2012 to Apr 2012 as reported by ClinicalTrials.gov.
- 12 Jan 2013 Actual initiation date changed from Mar 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.